Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity

Thomas P. Monath, Cynthia K. Lee, Justin G. Julander, Alicja Brown, David Beasley, Douglas M. Watts, Edward Hayman, Patrick Guertin, Joseph Makowiecki, Joseph Crowell, Philip Levesque, Gavin C. Bowick, Merribeth Morin, Elizabeth Fowler, Dennis W. Trent

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

In the last 10 years new concerns have arisen about safety of the live, attenuated yellow fever (YF) 17D vaccine, in particular viscerotropic adverse events, which have a case-fatality rate of 64%. A non-replicating cell culture-based vaccine would not cause these adverse events, and potentially could be used in persons with precautions or contraindications to use of the live vaccine, including age <9 months and >60 years, egg allergy, immune suppression, and pregnancy. We developed a whole virion vaccine from the 17D strain inactivated with β-propiolactone, and adsorbed to aluminum hydroxide. The inactivated vaccine was highly immunogenic in mice, hamsters, and cynomolgus macaques. After a single dose in hamsters and macaques, neutralizing antibody titers were similar to those elicited by the live 17D vaccine (YF-VAX®, Sanofi Pasteur). After two doses of inactivated vaccine, neutralizing antibody titers in hamsters were significantly higher than after a single dose of YF-VAX® [geometric mean titer (GMT) 20,480 vs. 1940, respectively (P < 0.001, ANOVA)]. Hamsters given a single dose or two doses of inactivated vaccine or a single dose of YF-VAX® were fully protected against hepatitis, viremia, weight loss and death after challenge with YF virus (Jimenez strain). A clinical trial of the inactivated vaccine (XRX-001) has been initiated.

Original languageEnglish (US)
Pages (from-to)3827-3840
Number of pages14
JournalVaccine
Volume28
Issue number22
DOIs
StatePublished - May 14 2010

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
Inactivated Vaccines
vaccine development
Cricetinae
inactivated vaccines
immune response
Yellow Fever
Safety
hamsters
Vaccines
Macaca
dosage
Neutralizing Antibodies
Egg Hypersensitivity
Propiolactone
live vaccines
vaccines
neutralizing antibodies
Aluminum Hydroxide

Keywords

  • Immune response
  • Inactivated vaccine
  • Yellow fever

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Inactivated yellow fever 17D vaccine : Development and nonclinical safety, immunogenicity and protective activity. / Monath, Thomas P.; Lee, Cynthia K.; Julander, Justin G.; Brown, Alicja; Beasley, David; Watts, Douglas M.; Hayman, Edward; Guertin, Patrick; Makowiecki, Joseph; Crowell, Joseph; Levesque, Philip; Bowick, Gavin C.; Morin, Merribeth; Fowler, Elizabeth; Trent, Dennis W.

In: Vaccine, Vol. 28, No. 22, 14.05.2010, p. 3827-3840.

Research output: Contribution to journalArticle

Monath, TP, Lee, CK, Julander, JG, Brown, A, Beasley, D, Watts, DM, Hayman, E, Guertin, P, Makowiecki, J, Crowell, J, Levesque, P, Bowick, GC, Morin, M, Fowler, E & Trent, DW 2010, 'Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity', Vaccine, vol. 28, no. 22, pp. 3827-3840. https://doi.org/10.1016/j.vaccine.2010.03.023
Monath, Thomas P. ; Lee, Cynthia K. ; Julander, Justin G. ; Brown, Alicja ; Beasley, David ; Watts, Douglas M. ; Hayman, Edward ; Guertin, Patrick ; Makowiecki, Joseph ; Crowell, Joseph ; Levesque, Philip ; Bowick, Gavin C. ; Morin, Merribeth ; Fowler, Elizabeth ; Trent, Dennis W. / Inactivated yellow fever 17D vaccine : Development and nonclinical safety, immunogenicity and protective activity. In: Vaccine. 2010 ; Vol. 28, No. 22. pp. 3827-3840.
@article{747dd0cd8dbe45888fedf38f26d9aaa9,
title = "Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity",
abstract = "In the last 10 years new concerns have arisen about safety of the live, attenuated yellow fever (YF) 17D vaccine, in particular viscerotropic adverse events, which have a case-fatality rate of 64{\%}. A non-replicating cell culture-based vaccine would not cause these adverse events, and potentially could be used in persons with precautions or contraindications to use of the live vaccine, including age <9 months and >60 years, egg allergy, immune suppression, and pregnancy. We developed a whole virion vaccine from the 17D strain inactivated with β-propiolactone, and adsorbed to aluminum hydroxide. The inactivated vaccine was highly immunogenic in mice, hamsters, and cynomolgus macaques. After a single dose in hamsters and macaques, neutralizing antibody titers were similar to those elicited by the live 17D vaccine (YF-VAX{\circledR}, Sanofi Pasteur). After two doses of inactivated vaccine, neutralizing antibody titers in hamsters were significantly higher than after a single dose of YF-VAX{\circledR} [geometric mean titer (GMT) 20,480 vs. 1940, respectively (P < 0.001, ANOVA)]. Hamsters given a single dose or two doses of inactivated vaccine or a single dose of YF-VAX{\circledR} were fully protected against hepatitis, viremia, weight loss and death after challenge with YF virus (Jimenez strain). A clinical trial of the inactivated vaccine (XRX-001) has been initiated.",
keywords = "Immune response, Inactivated vaccine, Yellow fever",
author = "Monath, {Thomas P.} and Lee, {Cynthia K.} and Julander, {Justin G.} and Alicja Brown and David Beasley and Watts, {Douglas M.} and Edward Hayman and Patrick Guertin and Joseph Makowiecki and Joseph Crowell and Philip Levesque and Bowick, {Gavin C.} and Merribeth Morin and Elizabeth Fowler and Trent, {Dennis W.}",
year = "2010",
month = "5",
day = "14",
doi = "10.1016/j.vaccine.2010.03.023",
language = "English (US)",
volume = "28",
pages = "3827--3840",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Inactivated yellow fever 17D vaccine

T2 - Development and nonclinical safety, immunogenicity and protective activity

AU - Monath, Thomas P.

AU - Lee, Cynthia K.

AU - Julander, Justin G.

AU - Brown, Alicja

AU - Beasley, David

AU - Watts, Douglas M.

AU - Hayman, Edward

AU - Guertin, Patrick

AU - Makowiecki, Joseph

AU - Crowell, Joseph

AU - Levesque, Philip

AU - Bowick, Gavin C.

AU - Morin, Merribeth

AU - Fowler, Elizabeth

AU - Trent, Dennis W.

PY - 2010/5/14

Y1 - 2010/5/14

N2 - In the last 10 years new concerns have arisen about safety of the live, attenuated yellow fever (YF) 17D vaccine, in particular viscerotropic adverse events, which have a case-fatality rate of 64%. A non-replicating cell culture-based vaccine would not cause these adverse events, and potentially could be used in persons with precautions or contraindications to use of the live vaccine, including age <9 months and >60 years, egg allergy, immune suppression, and pregnancy. We developed a whole virion vaccine from the 17D strain inactivated with β-propiolactone, and adsorbed to aluminum hydroxide. The inactivated vaccine was highly immunogenic in mice, hamsters, and cynomolgus macaques. After a single dose in hamsters and macaques, neutralizing antibody titers were similar to those elicited by the live 17D vaccine (YF-VAX®, Sanofi Pasteur). After two doses of inactivated vaccine, neutralizing antibody titers in hamsters were significantly higher than after a single dose of YF-VAX® [geometric mean titer (GMT) 20,480 vs. 1940, respectively (P < 0.001, ANOVA)]. Hamsters given a single dose or two doses of inactivated vaccine or a single dose of YF-VAX® were fully protected against hepatitis, viremia, weight loss and death after challenge with YF virus (Jimenez strain). A clinical trial of the inactivated vaccine (XRX-001) has been initiated.

AB - In the last 10 years new concerns have arisen about safety of the live, attenuated yellow fever (YF) 17D vaccine, in particular viscerotropic adverse events, which have a case-fatality rate of 64%. A non-replicating cell culture-based vaccine would not cause these adverse events, and potentially could be used in persons with precautions or contraindications to use of the live vaccine, including age <9 months and >60 years, egg allergy, immune suppression, and pregnancy. We developed a whole virion vaccine from the 17D strain inactivated with β-propiolactone, and adsorbed to aluminum hydroxide. The inactivated vaccine was highly immunogenic in mice, hamsters, and cynomolgus macaques. After a single dose in hamsters and macaques, neutralizing antibody titers were similar to those elicited by the live 17D vaccine (YF-VAX®, Sanofi Pasteur). After two doses of inactivated vaccine, neutralizing antibody titers in hamsters were significantly higher than after a single dose of YF-VAX® [geometric mean titer (GMT) 20,480 vs. 1940, respectively (P < 0.001, ANOVA)]. Hamsters given a single dose or two doses of inactivated vaccine or a single dose of YF-VAX® were fully protected against hepatitis, viremia, weight loss and death after challenge with YF virus (Jimenez strain). A clinical trial of the inactivated vaccine (XRX-001) has been initiated.

KW - Immune response

KW - Inactivated vaccine

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=77952322608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952322608&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.03.023

DO - 10.1016/j.vaccine.2010.03.023

M3 - Article

C2 - 20347059

AN - SCOPUS:77952322608

VL - 28

SP - 3827

EP - 3840

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -